8,356 Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) Acquired by SG Americas Securities LLC

SG Americas Securities LLC acquired a new stake in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 8,356 shares of the company’s stock, valued at approximately $367,000.

Other large investors have also recently added to or reduced their stakes in the company. Squarepoint Ops LLC grew its holdings in shares of Structure Therapeutics by 4.5% during the 2nd quarter. Squarepoint Ops LLC now owns 14,449 shares of the company’s stock valued at $567,000 after acquiring an additional 617 shares in the last quarter. Sandia Investment Management LP purchased a new position in Structure Therapeutics in the second quarter valued at about $39,000. Quarry LP acquired a new position in Structure Therapeutics in the 2nd quarter worth about $79,000. Teachers Retirement System of The State of Kentucky increased its position in Structure Therapeutics by 17.8% in the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 13,733 shares of the company’s stock worth $589,000 after purchasing an additional 2,077 shares during the last quarter. Finally, TrueMark Investments LLC raised its stake in shares of Structure Therapeutics by 13.5% during the 1st quarter. TrueMark Investments LLC now owns 29,884 shares of the company’s stock worth $1,281,000 after purchasing an additional 3,562 shares in the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Analysts Set New Price Targets

GPCR has been the topic of a number of research reports. JMP Securities dropped their price objective on Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating on the stock in a report on Friday, August 9th. Cantor Fitzgerald reissued an “overweight” rating and issued a $65.00 target price on shares of Structure Therapeutics in a research report on Monday, September 23rd. Finally, Morgan Stanley assumed coverage on shares of Structure Therapeutics in a report on Monday, September 23rd. They set an “overweight” rating and a $118.00 price target on the stock. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $87.83.

Structure Therapeutics Stock Down 0.3 %

Shares of Structure Therapeutics stock opened at $39.50 on Friday. Structure Therapeutics Inc. has a 12-month low of $26.61 and a 12-month high of $75.02. The stock has a market capitalization of $1.84 billion, a P/E ratio of -51.30 and a beta of -3.53. The stock has a 50 day moving average price of $39.34 and a two-hundred day moving average price of $39.87.

Structure Therapeutics (NASDAQ:GPCR) last posted its earnings results on Thursday, August 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05. Sell-side analysts anticipate that Structure Therapeutics Inc. will post -0.79 earnings per share for the current year.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.